{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:33:33Z","timestamp":1787758413678,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n                    To report the regional locations of metastases and to estimate the prognostic value of the pattern of regional metastases in men with metastatic hormone-sensitive prostate cancer (mHSPC), we retrospectively analyzed 870 mHSPC patients between November 28, 2009, and February 4, 2021, from West China Hospital in Chengdu, China. The patients were initially classified into 5 subgroups according to metastatic patterns as follows: simple bone metastases (G1), concomitant bone and regional lymph node (LN) metastases (G2), concomitant bone and nonregional LN (NRLN) metastases (G3), lung metastases (G4), and liver metastases (G5). In addition, patients in the G3 group were subclassified as G3a and G3b based on the LN metastatic plane (below or above the diaphragm, respectively). The associations of different metastatic patterns with castration-resistant prostate cancer-free survival (CFS) and overall survival (OS) were analyzed by univariate and multivariate analyses. The results showed that patients in G1 and G2 had relatively favorable clinical outcomes, patients in G3a and G4 had intermediate prognoses, and patients in G3b and G5 had the worst survival outcomes. We observed that patients in G3b had outcomes comparable to those in G5 but had a significantly worse prognosis than patients in G3a (median CFS: 8.2 months\n                    <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                    14.3 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.015; median OS: 38.1 months\n                    <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                    45.8 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.038). In conclusion, metastatic site can predict the prognosis of patients with mHSPC, and the presence of concomitant bone and NRLN metastases is a valuable prognostic factor. Furthermore, our findings indicate that the farther the NRLNs are located, the more aggressive the disease is.\n                  <\/jats:p>","DOI":"10.4103\/aja202270","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T10:48:14Z","timestamp":1667299694000},"page":"462-467","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Regional location of lymph node metastases predicts survival in patients with de novo metastatic prostate cancer"],"prefix":"10.4103","volume":"25","author":[{"given":"Zhi-Peng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ge","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Department of Urology, The Third People\u2019s Hospital of Chengdu, Chengdu 610031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Xi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations","volume":"14","author":"Tosoian","year":"2017","journal-title":"Nat Rev Urol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.14400","article-title":"Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer","volume":"123","author":"Ali","year":"2019","journal-title":"BJU Int"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bju.15632","article-title":"Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer","volume":"130","author":"Heesterman","year":"2022","journal-title":"BJU Int"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/BF02252994","article-title":"Prognostic significance of location of lymph node metastases in colorectal cancer","volume":"35","author":"Shida","year":"1992","journal-title":"Dis Colon Rectum"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00268-012-1427-1","article-title":"Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer","volume":"36","author":"de Meer","year":"2012","journal-title":"World J Surg"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/SLA.0000000000001767","article-title":"Prognostic significance of the location of lymph node metastases in patients with adenocarcinoma of the distal esophagus or gastroesophageal junction","volume":"264","author":"Anderegg","year":"2016","journal-title":"Ann Surg"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00345-016-1954-8","article-title":"PET imaging for lymph node dissection in prostate cancer","volume":"35","author":"Incerti","year":"2017","journal-title":"World J Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:13:08Z","timestamp":1787757188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202270","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"2022-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}